Skip to Content
Merck
All Photos(1)

Documents

O-004

Supelco

Oxymorphone solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C17H19NO4
CAS Number:
Molecular Weight:
301.34
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

drug control

Narcotic Licence Schedule A (Switzerland); estupefaciente (Spain); Decreto Lei 15/93: Tabela IA (Portugal)

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

forensics and toxicology

format

single component solution

storage temp.

2-8°C

SMILES string

CN1CC[C@]23[C@H]4Oc5c(O)ccc(C[C@@H]1[C@]2(O)CCC4=O)c35

InChI

1S/C17H19NO4/c1-18-7-6-16-13-9-2-3-10(19)14(13)22-15(16)11(20)4-5-17(16,21)12(18)8-9/h2-3,12,15,19,21H,4-8H2,1H3/t12-,15+,16+,17-/m1/s1

InChI key

UQCNKQCJZOAFTQ-ISWURRPUSA-N

Gene Information

Looking for similar products? Visit Product Comparison Guide

General description

A certified Snap-N-Spike® solution of oxymorphone suitable for use in a variety of GC/MS or LC/MS applications from pain prescription monitoring, clinical toxicology, and pharmaceutical research to forensic analysis and urine drug testing. Oxymorphone, sold under trade names such as Opana®, Numorphan®, and Numorphone, is an opiate analgesic indicated for the relief of moderate to severe pain.

Application


  • Advanced UHPLC-MS/MS Methodology: A novel ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) method has been developed for quantifying oxymorphone along with other opioids in various human tissues. This technique is crucial for understanding the pharmacokinetics and tissue distribution of synthetic opioids, providing valuable data for both clinical and pharmaceutical research (Manca et al., 2023).

  • Genetic Association Studies: Oxymorphone′s application extends to genetic studies where its interaction with the CYP2D6 genotype is analyzed to determine individual responses in opioid analgesia. This research is critical for optimizing pain management strategies and reducing adverse effects in treatments involving synthetic opioids (Merchant et al., 2022).

  • Drug Safety and Regulation: Oxymorphone is a focus of regulatory review processes, particularly in the context of the opioid crisis. Analyzing the decisions and advisories concerning oxymorphone helps in understanding its role in current medical practice and its impact on public health policies (Litman, 2020).

  • Innovative Analytical Techniques: Research includes the development of advanced analytical techniques, such as gas chromatography-mass spectrometry, for detecting oxymorphone in biological samples. These methods are essential for clinical diagnostics and forensic investigations, ensuring accurate and sensitive detection of this potent analgesic (Norouzi et al., 2020).

  • In Vitro Safety Evaluations: Oxymorphone is also studied in in vitro models to assess its hemolytic potential when abused intravenously. This research is crucial for understanding the risks associated with non-prescribed administration routes and contributes to safer pharmaceutical formulations (Persich et al., 2020).

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Numorphan is a registered trademark of Endo Pharmaceuticals Inc.
Opana is a registered trademark of Endo Pharmaceuticals Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Target Organs

Eyes

Storage Class Code

3 - Flammable liquids

WGK

WGK 2

Flash Point(F)

49.5 °F - closed cup

Flash Point(C)

9.7 °C - closed cup


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Caroline Raasch Alquist et al.
The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society, 164(3), 145-146 (2012-08-08)
Following a hypoxic-ischemic insult, the globus pallidus is selectively spared from ischemic injury in contrast to the caudate and putamen. The known causes for hemorrhagic and necrotic lesions selective for injuring the globus pallidus are varied but few. The most
Irma H Benedek et al.
Drug design, development and therapy, 5, 455-463 (2011-12-14)
A formulation of crush-resistant extended-release opioids may deter abuse. The purpose of this study was to evaluate the bioequivalence of oxymorphone extended-release (Oxy-ER) and a crush-resistant formulation of oxymorphone extended-release (Oxy-CRF). In three open-label, randomized studies, healthy adults at a
William D Fiske et al.
The journal of pain : official journal of the American Pain Society, 13(1), 90-99 (2012-01-03)
Adverse events may occur with an extended-release (ER) opioid if tampering or coadministration with ethanol causes excessive exposure (dose dumping) to the opioid. The effects of ethanol on the in vitro dissolution and in vivo pharmacokinetics of oxymorphone ER and
Susruta Majumdar et al.
Bioorganic & medicinal chemistry letters, 21(13), 4001-4004 (2011-05-31)
Tritiated opioid radioligands have proven valuable in exploring opioid binding sites. However, tritium has many limitations. Its low specific activity and limited counting efficiency makes it difficult to examine low abundant, high affinity sites and its disposal is problematic due
Kerri A Schoedel et al.
Journal of opioid management, 7(3), 179-192 (2011-08-10)
To compare the subjective effects of oxymorphone extended release (OM-ER) versus oxycodone controlled release (OC-CR). Randomized, double-blind, crossover study. Inpatient unit. Healthy, nondependent recreational opioid users. Single intact oral tablets that were placebo or contained OM-ER (15 and 30 mg)

Articles

Although both biphenyl and phenyl-hexyl phases can resolve these compounds, the former exhibits excellent peak shape and substantially less silanol-derived ion exchange activity.

Protocols

Optimize β-glucuronidase hydrolysis for glucuronide metabolite analysis considering factors like time, temperature, pH, and enzyme concentration.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service